NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
94 hedge funds and large institutions have $50.6M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 35 reducing their positions, and 24 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 106 → 94 (-12)
14% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 35
50% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 24
59% less capital invested
Capital invested by funds: $124M → $50.6M (-$73.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.79M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$569K |
| 3 |
Renaissance Technologies
New York
|
+$558K |
| 4 |
EC
Euclidean Capital
New York
|
+$508K |
| 5 |
Squarepoint
New York
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.64M |
| 2 |
Morgan Stanley
New York
|
-$871K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$601K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$477K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$377K |
NGM Hedge Fund Activity: Q3 2023 in Review
94 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q3 2023, worth a combined $50.6M — down 59% from $124M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of NGM and 12 opened new positions — a net loss of 12 holders — while 35 trimmed existing stakes and 30 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.79M. The largest seller was BlackRock, cutting an estimated $1.64M.
- 94 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q3 2023, down from 106 in Q2 2023.
- Funds reported $50.6M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q3 2023, down 59% quarter-over-quarter.
- 12 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q3 2023 and 24 closed out, a net change of -12 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q3 2023 was JP Morgan Chase, an estimated $1.79M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q3 2023 was BlackRock, an estimated $1.64M sold.
Based on aggregated 13F filings for Q3 2023.